IFNA2 and neoplasm: A large randomized study of BCG vs. BCG plus IFN-α2b in BCG-naïve patients with NMIBC revealed that BCG plus IFN-α2b did not decrease tumor recurrence and increased the prevalence of side effects compared to BCG alone [94].